XTRA:BAYNPharmaceuticals
Is Bayer (XTRA:BAYN) Undervalued On REVEAL Trial Success Or Is That Priced In?
How Bayer’s REVEAL data intersects with recent stock performance
Bayer (XTRA:BAYN) is in focus after the Phase III REVEAL study of iodine 124 evuzamitide for diagnosing cardiac amyloidosis met its primary endpoints on sensitivity and specificity, with data shared at a leading cardiology congress.
For shareholders, the news arrives after a strong run in the stock. Bayer shares closed at €49.04 on 29 August 2026, with total return over the past month at 2.1% and over the past 3 months at...